Alnylam Pharmaceuticals
ALNY
#618
Rank
โ‚น2.779 T
Marketcap
โ‚น21,473
Share price
3.69%
Change (1 day)
79.37%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น350.83. In 2022 the company made an earnings per share (EPS) of -โ‚น792.99 a decrease over its 2021 EPS that were of -โ‚น614.59.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-57.48%
2022-โ‚น792.9929.03%
2021-โ‚น614.59-3.36%
2020-โ‚น635.93-8.48%
2019-โ‚น694.837.67%
2018-โ‚น645.3239.74%
2017-โ‚น461.8012.94%
2016-โ‚น408.8738.84%
2015-โ‚น294.49-32.88%
2014-โ‚น438.75259.44%
2013-โ‚น122.06-31.25%
2012-โ‚น177.5552.94%
2011-โ‚น116.0930.77%
2010-โ‚น88.77-8.77%
2009-โ‚น97.3178.13%
2008-โ‚น54.63-70.78%
2007-โ‚น186.9499.09%
2006-โ‚น93.90-43.88%
2005-โ‚น167.31-82.33%
2004-โ‚น946.93-59.23%
2003-โ‚น2,323

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น145.11-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,189-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น668.37 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.05-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น144.26-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น319.25-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น271.47-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น170.72-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel